Associated Papers
Utility of Next-Generation Sequencing in Renal Neoplasia, Including Tumors With Clear Cytoplasm and Rare Phenotypes (ELOC/MITF Alterations and Mismatch Repair Deficiency).
McCarthy M et al.
Mayo Clinic Proceedings, 2026
ELOC-mutated Renal Cell Carcinoma: Clinicopathologic, Immunohistochemical, and Molecular Genetic Analysis of 35 Cases.
Hou J et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2026
Multigenerational VHL family characterized by pathogenic germline ELOC variant: Response to belzutifan.
Vocke CD et al.
Urologic Oncology, 2026
Dysregulation of the ubiquitin-proteasome system in von Hippel-Lindau syndrome: molecular insights and clinical perspectives.
Bi Y et al.
Clinical and Experimental Medicine, 2025
Comprehensive Analysis of 15 Cases of ELOC -RCC and Identification of Novel Mutation Site.
Wu Y et al.
The American Journal of Surgical Pathology, 2025
ELOC-Mutated Renal Cell Carcinoma is a Rare Indolent Tumor With Distinctive Genomic Characteristics.
Wang JJ et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
A case report: identifying a novel variant in ELOC(TCEB1)-mutant renal cell carcinoma.
Cheng HP et al.
Frontiers in Oncology, 2025
ELOC(TCEB1)-mutated renal cell carcinoma: a case report and clinicopathological analysis.
Zhu Y et al.
Frontiers in Oncology, 2025
Characteristics, aetiology and implications for management of multiple primary renal tumours: a systematic review.
Zhang H et al.
European Journal of Human Genetics : Ejhg, 2024
Genomic alterations and diagnosis of renal cancer.
Zhang X et al.
Virchows Archiv : an International Journal of Pathology, 2024
Computational analysis of protein-protein interactions of cancer drivers in renal cell carcinoma.
Pei J et al.
Febs Open Bio, 2024
[Clinicopathological and molecular genetic characteristics of ELOC mutated renal cell carcinoma].
Wen Z et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2023
Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.
Li H et al.
The American Journal of Surgical Pathology, 2023
Biallelic ELOC-Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity.
Batavia AA et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2023
Genomic profiles of renal cell carcinoma in a small Chinese cohort.
Tai S et al.
Frontiers in Oncology, 2023
Elongin C (ELOC/TCEB1)-associated von Hippel-Lindau disease.
Andreou A et al.
Human Molecular Genetics, 2022
Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma.
Wang Y et al.
Pathology, Research and Practice, 2022
"Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB et al.
The American Journal of Surgical Pathology, 2020
Analysis of error profiles in deep next-generation sequencing data.
Ma X et al.
Genome Biology, 2019
Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?
Batavia AA et al.
Histopathology, 2019
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype.
Hakimi AA et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2015
Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.
Shankar GM et al.
Acta Neuropathologica Communications, 2014
Integrated molecular analysis of clear-cell renal cell carcinoma.
Sato Y et al.
Nature Genetics, 2013